JP Morgan Chase
AVBP icon

JP Morgan Chase’s ArriVent BioPharma AVBP Stock Holding History

JP Morgan Chase’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Sell
65,879
-3,515
-5% -$79.4K ﹤0.01% 4378
2025
Q4 		$1.4M Buy
69,394
+55,403
+396% +$1.15M ﹤0.01% 4374
2025
Q3 		$258K Sell
13,991
-418
-3% -$8.21K ﹤0.01% 5378
2025
Q2 		$314K Sell
14,409
-1,920
-12% -$39.9K ﹤0.01% 5010
2025
Q1 		$302K Buy
16,329
+644
+4% +$15.8K ﹤0.01% 5066
2024
Q4 		$418K Buy
15,685
+3,240
+26% +$93K ﹤0.01% 5137
2024
Q3 		$292K Buy
12,445
+8,050
+183% +$183K ﹤0.01% 5220
2024
Q2 		$81.5K Sell
4,395
-8,161
-65% -$146K ﹤0.01% 5629
2024
Q1 		$224K Buy
+12,556
New +$253K ﹤0.01% 5289

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase's AVBP Position: Q1 2026 in Review

JP Morgan Chase reduced its ArriVent BioPharma (AVBP) stake by 5.1% in Q1 2026, selling an estimated $79.4K and leaving 65,879 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4378.

JP Morgan Chase first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.4M in Q4 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • JP Morgan Chase held 65,879 shares of ArriVent BioPharma worth $1.38M as of Q1 2026.
  • JP Morgan Chase sold 3,515 ArriVent BioPharma shares in Q1 2026, an estimated $79.4K.
  • ArriVent BioPharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4378 holding.
  • JP Morgan Chase first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • JP Morgan Chase's ArriVent BioPharma position peaked at $1.4M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.